ALNYLAM PHARMACEUTICALS, INC. (ALNY) › Cost of RevenueALNYLAM PHARMACEUTICALS, INC. (ALNY) — Cost of RevenueAnnual figures by period end, from SEC filings.2017-12-31: $02018-12-31: $1.80M2019-12-31: $25.06M2020-12-31: $74.19M2021-12-31: $115.00M2022-12-31: $140.17M2023-12-31: $268.22M2024-12-31: $306.51M2025-12-31: $677.17M$677.17M2017-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$677.17M+120.9%2026-02-12From 2025-01-012024-12-31$306.51M+14.3%2026-02-12From 2024-01-012023-12-31$268.22M+91.3%2026-02-12From 2023-01-012022-12-31$140.17M+21.9%2025-02-13From 2022-01-012021-12-31$115.00M+55.0%2024-02-15From 2021-01-012020-12-31$74.19M+196.0%2023-02-23From 2020-01-012019-12-31$25.06M+1290.8%2022-02-10From 2019-01-012018-12-31$1.80M—2021-02-11From 2018-01-012017-12-31$0—2020-02-13From 2017-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)